Related Experiment Video

Updated: Jul 14, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis

M Paul1, A D Nielsen, A Gafter-Gvili

  • 1Department of Medicine E, Rabin Medical Center, Beilinson Hospital, 49100 Petah-Tiqva, Israel.

The European Respiratory Journal
|June 1, 2007
PubMed

Insights

This study found that combination therapy for community-acquired pneumonia showed similar 30-day mortality to monotherapy after propensity score matching. Observational studies may not reliably assess combination therapy benefits due to differing prescription patterns.

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacology
  • Epidemiology

Background:

  • Community-acquired pneumonia (CAP) treatment often involves beta-lactam monotherapy or combination therapy.
  • Observational studies are crucial for evaluating real-world treatment effectiveness but require robust statistical adjustment for confounding factors.

Purpose of the Study:

  • To compare the 30-day mortality and hospital stay of hospitalized patients with CAP treated with beta-lactam monotherapy versus beta-lactam and macrolide combination therapy.
  • To assess the utility of propensity score matching in adjusting for patient differences in observational studies of CAP treatment.

Main Methods:

  • A prospective, multinational observational study involving 169 patients on monotherapy and 282 on combination therapy.
  • Propensity scores were developed using baseline patient and infection characteristics to match patients.
  • 30-day mortality and hospital stay were compared between matched groups; logistic regression adjusted for propensity score and Pneumonia Severity Index.

Main Results:

  • Unadjusted 30-day mortality was significantly higher in the monotherapy group (22%) compared to the combination therapy group (7%).
  • After propensity score matching, only 27 pairs of patients were identified, with identical 30-day mortality (11% each).
  • The multivariable odds ratio for mortality with combination therapy was 0.69 (95% CI 0.32-1.48), indicating no statistically significant benefit.

Conclusions:

  • The propensity to prescribe combination therapy versus monotherapy differs significantly, complicating reliable assessment in observational studies.
  • Propensity score matching, while attempting to control for confounders, resulted in a small matched cohort, limiting definitive conclusions on treatment efficacy.
  • Further research, potentially randomized controlled trials, may be needed to definitively establish the comparative effectiveness of combination therapy for CAP.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: